Percent-predicted 6-minute walk distance in duchenne muscular dystrophy to account for maturational influences.
about
Asfotase alfa therapy for children with hypophosphatasia.Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy24 month longitudinal data in ambulant boys with Duchenne muscular dystrophyThe burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence reviewThe 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years.Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension StudyThe cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing anThe cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional studyAtaluren treatment of patients with nonsense mutation dystrophinopathy.Proof of concept of the ability of the kinect to quantify upper extremity function in dystrophinopathyThe 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year.The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular diseaseThe NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass SpectrometryThe 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter studyCirculating Biomarkers for Duchenne Muscular Dystrophy.Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy.Why short stature is beneficial in Duchenne muscular dystrophy.Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes.Weakness and fatigue in diverse neuromuscular diseases.Muscle MRI and functional outcome measures in Becker muscular dystrophy.Electrical impedance myography in Duchenne muscular dystrophy and healthy controls: A multicenter study of reliability and validity.Muscle ultrasound quantifies disease progression over time in infants and young boys with duchenne muscular dystrophy.
P2860
Q27334025-3A101AB6-1722-4627-A878-219C6966202AQ28554686-C82CB55C-95D4-4FD9-B663-5B91DD650879Q30000819-6E8FF66C-006F-44B5-853C-1762B65AF1F4Q30234649-45E3F9B1-99B3-4884-935E-9FCC94075AACQ30557216-AE24840B-E1B2-4037-B2A3-00F9CF154C90Q30856806-9F82EC70-109A-45AF-B4F1-2D9F077358BFQ31147166-28D62BCF-B01D-4DB6-A705-38E2F91B42EFQ33435110-B756D8BB-E674-4F92-AF1F-73C516B48412Q33919009-8B428065-2AB1-4BCE-9F0A-3498B50CB141Q34103360-E81BEF72-EE9F-44A4-B8CA-E64710B67201Q34155950-9C303E07-2979-430A-B300-53AF7FFE1A4CQ34561960-34C68043-641C-432E-B5EC-E01F3CC9C674Q34630606-14416BAE-99BC-4BD3-993F-B5E7177C3220Q34836557-7715E4AE-B016-4CBD-99A4-01374ECA6CA8Q36351131-9AD7DF49-D710-41EE-9C6B-268EAC099FEEQ36577433-D66F2B97-8D0F-49AA-8B79-20B90E20FB0FQ36812936-4915F415-1A8A-45A7-9416-9E92715CCEA7Q37298079-E2C67378-7A29-45A4-AF31-98FDD89D7F41Q37610530-E6FB93AD-F7AD-4724-A9C5-C8BE52BA69B8Q38125499-DC6B2D87-EDC5-4885-AA55-A60C7AA1BE30Q39376754-BD614711-283B-4493-AE53-155C64063391Q40316979-6861FFCB-AF24-4C3D-ADDD-3A8857CD596DQ41860015-4A1DB347-023E-4575-94AF-1D4487DA3990Q43449990-65DA8018-AE7D-4256-8C49-313D0EAE1901Q47102881-890ED69D-1EF6-4B79-8B66-A19DDF14BD2DQ53308303-F566EC77-4D4F-431C-AD71-EBC32346A4D8Q55093238-0C58C3C0-DF1F-428B-8B06-8836BAAE44C7
P2860
Percent-predicted 6-minute walk distance in duchenne muscular dystrophy to account for maturational influences.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Percent-predicted 6-minute wal ...... t for maturational influences.
@ast
Percent-predicted 6-minute wal ...... t for maturational influences.
@en
Percent-predicted 6-minute wal ...... t for maturational influences.
@nl
type
label
Percent-predicted 6-minute wal ...... t for maturational influences.
@ast
Percent-predicted 6-minute wal ...... t for maturational influences.
@en
Percent-predicted 6-minute wal ...... t for maturational influences.
@nl
prefLabel
Percent-predicted 6-minute wal ...... t for maturational influences.
@ast
Percent-predicted 6-minute wal ...... t for maturational influences.
@en
Percent-predicted 6-minute wal ...... t for maturational influences.
@nl
P2093
P2860
P50
P356
P1433
P1476
Percent-predicted 6-minute wal ...... t for maturational influences.
@en
P2093
Allen Reha
Erica Goude Keller
Erik Henricson
Gary Elfring
P2860
P304
P356
10.1371/CURRENTS.RRN1297
P577
2011-01-01T00:00:00Z